{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:20:55Z","timestamp":1793755255426,"version":"4.6.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,3,19]],"date-time":"2020-03-19T00:00:00Z","timestamp":1584576000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,3,19]],"date-time":"2020-03-19T00:00:00Z","timestamp":1584576000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>The spectrum of yeasts and their antifungal susceptibility profile are poorly known and treatment of fungal disease has remained empirical. The aim of this study is to determine the spectrum and antifungal susceptibility profile of yeasts particularly of <jats:italic>Candida<\/jats:italic> species.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>A descriptive study on the composition of <jats:italic>Candida<\/jats:italic> species and antifungal susceptibility profile were conducted from January 2018 to September 2018. Clinical samples collected from different sites were cultured on Sabouraud dextrose agar and incubated for an appropriate time. Identification of yeast isolates and their antifungal susceptibility profile were determined by the VITEK 2 compact system. Descriptive statistics such as frequency and percentage of <jats:italic>Candida<\/jats:italic> species were calculated using SPSS version 20.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Of 209 yeasts recovered, 104(49.8%), 90 (43.1%), 15(7.2%) were <jats:italic>C. albicans,<\/jats:italic> non <jats:italic>albicans Candida<\/jats:italic> species, and other yeasts, respectively. Among non <jats:italic>albicans Candida<\/jats:italic> species, <jats:italic>Candida krusei<\/jats:italic> was the commonest isolate. Of other yeast groups, 66.7% was represented <jats:italic>by Cryptococcus laurentii.<\/jats:italic> Regardless of <jats:italic>Candida<\/jats:italic> species identified, 85.6, 3.9, and 10.5% of the isolates were susceptible, intermediate, and resistant to fluconazole, respectively. <jats:italic>C krusei<\/jats:italic> was 100% resistant to the drug. Voriconazole demonstrated the greatest antifungal activity against <jats:italic>Candida<\/jats:italic> isolates in which 99.4% of <jats:italic>Candida<\/jats:italic> isolates were susceptible. The susceptibility and the resistance rate of <jats:italic>Candida<\/jats:italic> isolate to both caspofungin and micafungin were the same being 96 and 4% respectively. However, micafungin was more potent than caspofungin. The susceptibility, resistant, and intermediate rates of yeasts against flucytosine were, 86.2, 6.6, and 7.2%, respectively.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>The present study demonstrated the distribution of <jats:italic>Candida<\/jats:italic> species in different clinical specimens where the isolation rate of non-<jats:italic>albicans Candida<\/jats:italic> species was comparable to <jats:italic>Candida albicans<\/jats:italic>. The high resistance rate of <jats:italic>C. krusei<\/jats:italic> to fluconazole and flucytosine may demonstrate that the treatment of candidiasis empirically is questionable.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12879-020-4883-5","type":"journal-article","created":{"date-parts":[[2020,3,19]],"date-time":"2020-03-19T00:05:14Z","timestamp":1584576314000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":64,"title":["Distribution of Candida albicans and non-albicans Candida species isolated in different clinical samples and their in vitro antifungal suscetibity profile in Ethiopia"],"prefix":"10.1186","volume":"20","author":[{"given":"Elias","family":"Seyoum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adane","family":"Bitew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amete","family":"Mihret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,19]]},"reference":[{"key":"4883_CR1","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1086\/496922","volume":"41","author":"TE Zaoutis","year":"2005","unstructured":"Zaoutis TE, Argon J, Chu J, Berlin JA, Walsh TJ, Feudtner C. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis. 2005;41:1232\u20139.","journal-title":"Clin Infect Dis"},{"key":"4883_CR2","doi-asserted-by":"publisher","first-page":"2816","DOI":"10.1128\/JCM.00773-06","volume":"44","author":"AL Colombo","year":"2006","unstructured":"Colombo AL, Nucci M, Park BJ, Nou\u00e9r SA, Arthington-Skaggs B, da Matta DA, et al. Epidemiology of candidemia in Brazil: a nationwide sentinel surveillance of candidemia in eleven medical centers. J Clin Microbiol. 2006;44:2816\u201323.","journal-title":"J Clin Microbiol"},{"key":"4883_CR3","first-page":"1938","volume":"90","author":"CM Wilcox","year":"1995","unstructured":"Wilcox CM, Straub RF, Clark WS. Prospective evaluation of oropharyngeal findings in human immunodeficiency virus-infected patients with esophageal ulceration. American J gastroenterol. 1995;90:1938\u201341.","journal-title":"American J gastroenterol"},{"key":"4883_CR4","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1378\/chest.123.5_suppl.500S","volume":"123","author":"DR Snydman","year":"2003","unstructured":"Snydman DR. Shifting in patterns in the epidemiology of nosocomial Candida infections. Chest. 2003;123:500\u20133.","journal-title":"Chest"},{"key":"4883_CR5","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s11908-006-0016-6","volume":"8","author":"JD Sobel","year":"2006","unstructured":"Sobel JD. The emergence of non-albicans Candida species as causes of invasive candidiasis and candidemia. Curr Infct Dis Rep. 2006;8:427\u201333.","journal-title":"Curr Infct Dis Rep"},{"key":"4883_CR6","first-page":"113","volume":"1","author":"R Latha","year":"2011","unstructured":"Latha R, Sasikala R, Muruganandam RN, Babu RY. Study on the shifting patterns of Non Candida albicans Candida in lower respiratory tract infections and evaluation of the CHROMagar in identification of the Candida species. J Microbiol Biotech Res. 2011;1:113\u20139.","journal-title":"J Microbiol Biotech Res"},{"key":"4883_CR7","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/j.1439-0507.1997.tb00197.x","volume":"40","author":"M Knoke","year":"1997","unstructured":"Knoke M, Schulz K, Bernhardt H. Dynamics of Candida isolations from humans from 1992-1995 in Greifswald. Germany Mycoses. 1997;40:105\u201310.","journal-title":"Germany Mycoses"},{"key":"4883_CR8","first-page":"481","volume":"31","author":"JH Shin","year":"1999","unstructured":"Shin JH, Lim WH, Shin DH, Suh SP, Ryang DW. Candida species isolated from clinical specimens and medical personnel. Korean J Infect Dis. 1999;31:481\u20136.","journal-title":"Korean J Infect Dis"},{"key":"4883_CR9","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1007\/s11908-006-0017-5","volume":"8","author":"A Upton","year":"2006","unstructured":"Upton A, Marr AK. Emergence of opportunistic mold infections in the hematopoietic stem cell transplant patient. Curr Infect Dis Rep. 2006;8:434\u201341.","journal-title":"Curr Infect Dis Rep"},{"key":"4883_CR10","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1086\/380637","volume":"38","author":"O Marchetti","year":"2004","unstructured":"Marchetti O, Bille J, Fluckiger U, Eggimann P, Ruef C, Garbino J, et al. Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991\u20132000. Clin Infect Dis. 2004;38:311\u201320.","journal-title":"Clin Infect Dis"},{"key":"4883_CR11","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2147\/TCRM.S40160","volume":"10","author":"N Yapar","year":"2014","unstructured":"Yapar N. Epidemiology and risk factors for invasive candidiasis. Ther Clin Risk Manag. 2014;10:95\u2013105.","journal-title":"Ther Clin Risk Manag"},{"key":"4883_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1086\/668770","volume":"34","author":"DM Sievert","year":"2013","unstructured":"Sievert DM, Ricks P, Edwards JR, Schneider A, Patel J, Srinivasan A, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the national healthcare safety network at the centers for disease control and prevention, 2009\u20132010. Infect Control Hosp Epidemiol. 2013;34:1\u201314.","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"4","key":"4883_CR13","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1128\/JCM.41.4.1440-1446.2003","volume":"41","author":"M. A. Pfaller","year":"2003","unstructured":"Pfaller MA, Diekema DJ, Messer SA, Boyken L, Hollis RJ. Activities of fluconazole and voriconazole against 1,586 recent clinical isolates of Candida species determined by Broth microdilution, disk diffusion, and Etest methods: report from the ARTEMIS Global Antifungal Susceptibility program, 2001. J Clin Microbiol. 2003;41:1440\u20136.","journal-title":"Journal of Clinical Microbiology"},{"key":"4883_CR14","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1128\/AAC.01631-10","volume":"55","author":"O Zaragoza","year":"2011","unstructured":"Zaragoza O, Mesa-Arango AC, Gomez-Lopez A, Bernal-Martinez L, Rodriguez-Tudela JL, et al. A Process Analysis of Variables for Standardization of Antifungal Susceptibility Testing of Non-Fermentative Yeasts. Antimicrob Agents Chemother. 2011;55:1563\u201370.","journal-title":"Antimicrob Agents Chemother"},{"key":"4883_CR15","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1128\/JCM.01986-06","volume":"45","author":"MA Pfaller","year":"2007","unstructured":"Pfaller MA, Diekema DJ, Procop GW, Rinaldi MG. Multicenter comparison of the VITEK 2 yeast susceptibility test with the CLSI broth microdilution reference method for testing fluconazole against Candida spp. J Clin Microbiol. 2007;45:796\u2013802.","journal-title":"J Clin Microbiol"},{"key":"4883_CR16","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/1471-2334-13-82","volume":"13","author":"A Mulu","year":"2013","unstructured":"Mulu A, Kassu A, Anagaw B, Moges B, Gelaw A, Alemayehu M, et al. Frequent detection of \u2018azole\u2019 resistant Candida species among late presenting AIDS patients in northwest Ethiopia. BMC Infect Dis. 2013;13:82 http:\/\/www.biomedcentral.com\/1471-2334\/13\/82.","journal-title":"BMC Infect Dis"},{"key":"4883_CR17","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s12905-018-0607-z","volume":"18","author":"A Bitew","year":"2018","unstructured":"Bitew A, Abebaw Y. Vulvovaginal candidiasis: Species distribution of Candida and their antifungal susceptibility pattern. BMC Womens Health. 2018;18:94. https:\/\/doi.org\/10.1186\/s12905-018-0607-z.","journal-title":"BMC Womens Health"},{"key":"4883_CR18","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.ajme.2015.10.001","volume":"52","author":"DS ElFeky","year":"2016","unstructured":"ElFeky DS, Gohar NM, El-Seidi EH, Ezzat MM, Hassan S, AboElew SH. Species identification and antifungal susceptibility pattern of Candida isolates in cases of vulvovaginal candidiasis. Alexandria J Med. 2016;52:269\u201377.","journal-title":"Alexandria J Med"},{"key":"4883_CR19","doi-asserted-by":"publisher","first-page":"4","DOI":"10.4103\/0974-777X.77288","volume":"3","author":"V Mohandas","year":"2011","unstructured":"Mohandas V, Ballal M. Distribution of Candida Species in different clinical samples and their virulence: Biofilm formation, proteinase and phospholipase production: A study on hospitalized patients in Southern India. J Glob Infec Dis. 2011;3:4\u20138.","journal-title":"J Glob Infec Dis"},{"key":"4883_CR20","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.5455\/ijmsph.2016.26042016491","volume":"5","author":"KH Das","year":"2016","unstructured":"Das KH, Getso MI, Azeez-Akande O. Distribution of Candida albicans and non-albicans Candida in clinical samples and their intrinsic biofilm production status. Int J Med Sci Public Health. 2016;5:2443\u2013244. https:\/\/doi.org\/10.5455\/ijmsph.2016.26042016491.","journal-title":"Int J Med Sci Public Health"},{"key":"4883_CR21","first-page":"109","volume":"8","author":"H Sida","year":"2017","unstructured":"Sida H, Pethani J, Dalal P, Hiral SH. Study of Changing Trend in the Clinical Distribution of Candida Species in Various Clinical Samples at Tertiary Care Hospital, Ahmedabad, Gujarat. Ntl J Community Med. 2017;8:109\u201311.","journal-title":"Ntl J Community Med"},{"key":"4883_CR22","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/j.archoralbio.2015.03.002","volume":"60","author":"T Muadcheingka","year":"2015","unstructured":"Muadcheingka T, Tantivitayakul P. Distribution of Candida albicans and non-albicans Candida species in oral candidiasis patients: Correlation between cell surface hydrophobicity and biofilm forming activities. Archive oral biol. 2015;60:894\u2013901.","journal-title":"Archive oral biol"},{"key":"4883_CR23","first-page":"369e375","volume":"44","author":"H-W Chi","year":"2011","unstructured":"Chi H-W, Yang Y-S, Shang S-T, Chen K-H, Yeh K-M, Chang F-Y, et al. Candida albicans versus non-albicans bloodstream infections: The comparison of risk factors and outcome. J Microbiol, Immun Infec. 2011;44:369e375.","journal-title":"J Microbiol, Immun Infec"},{"key":"4883_CR24","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.apjtb.2015.12.019","volume":"6","author":"R Kaur","year":"2016","unstructured":"Kaur R, Dhakad MS, Goyal Kumar RR. Emergence of non-albicans Candida species and antifungal resistance in intensive care unit patients. Asian Pac J Trop Biomed. 2016;6:455\u201360.","journal-title":"Asian Pac J Trop Biomed"},{"key":"4883_CR25","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.oooo.2015.03.008","volume":"120","author":"ALR Ribeiro","year":"2015","unstructured":"Ribeiro ALR, de Alencar Menezes TO, de Melo Alves-Junior S, de Menezes SF, Silvia Helena Marques-da-Silva SH, Ros\u00e1rio Vallinoto ACR. Oral carriage of Candida species in HIV-infected patients during highly active antiretroviral therapy (HAART) in Bel\u00e9m, Brazil. Oral Surg Oral Med Oral Pathol Oral Radiol. 2015;120:29\u201333.","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"4883_CR26","doi-asserted-by":"publisher","first-page":"e124","DOI":"10.1111\/j.1439-0507.2011.02165.x","volume":"55","author":"AF Schmalrec","year":"2012","unstructured":"Schmalrec AF, Willinger B, Haase BG, Lass-Flo C, Feeler K, et al. Species and susceptibility distribution of 1062 clinical yeast isolates to azoles, echinocandins, flucytosine and amphotericin B from a multi-centre study. Mycoses. 2012;55:e124\u201337.","journal-title":"Mycoses"},{"issue":"5","key":"4883_CR27","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1128\/JCM.43.5.2155-2162.2005","volume":"43","author":"S. S. Richter","year":"2005","unstructured":"Richter SS, Galask RP, Messer SA, Hollis RJ, Diekema DJ, Pfaller MA. Antifungal Susceptibilities of Candida Species Causing Vulvovaginitis and Epidemiology of Recurrent Cases. J Clin Microbial. 2005;45:2155\u201362. https:\/\/doi.org\/10.1128\/JCM.43.5.2155-2162.2005.","journal-title":"Journal of Clinical Microbiology"},{"key":"4883_CR28","first-page":"183","volume":"3","author":"P Badiee","year":"2011","unstructured":"Badiee P, Alborzi A. Susceptibility of clinical Candida species isolates to antifungal agents by E-test, Southern Iran: A five year study. Iran J MicrobioL. 2011;3:183\u20138.","journal-title":"Iran J MicrobioL"},{"key":"4883_CR29","first-page":"401","volume":"98","author":"P Godoy","year":"2003","unstructured":"Godoy P, Tiraboschi IN, Severo LC, Beatriz Bustamante B, Calvo B, de Almeida LP, et al. Species Distribution and Antifungal Susceptibility Profile of Candida spp. Bloodstream Isolates from Latin American Hospitals.Mem Inst Oswaldo Cruz. Rio de Janeiro. 2003;98:401\u20135.","journal-title":"Rio de Janeiro"},{"key":"4883_CR30","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1111\/myc.12661","volume":"60","author":"M Sasso","year":"2017","unstructured":"Sasso M, Roger C, Sasso M, Poujol H, Saber Barbar S, Lefrant J. Changes in the distribution of colonising and infecting Candida spp. isolates, antifungal drug consumption and susceptibility in a French intensive care unit: A 10-year study. Mycoses. 2017;60:770\u201380.","journal-title":"Mycoses"},{"key":"4883_CR31","doi-asserted-by":"publisher","unstructured":"Mnge P, OkeleyeBI, Vasaikar SD, Apalata T. Species distribution and antifungal susceptibility patterns of Candida isolates from a public tertiary teaching hospital in the Eastern Cape Province, South Africa. Braz J Med Biol Res. 2016. https:\/\/doi.org\/10.1590\/1414-431X20175797.","DOI":"10.1590\/1414-431X20175797"},{"key":"4883_CR32","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1186\/s12879-019-4588-9","volume":"19","author":"Z Zeng","year":"2019","unstructured":"Zeng Z, Tian G, Ding Y, Yang K, Liu J, Deng J. Surveillance study of the prevalence, species distribution, antifungal susceptibility, risk factors and mortality of invasive candidiasis in a tertiary teaching hospital in Southwest China. BMC Infect Dis. 2019;19:939. https:\/\/doi.org\/10.1186\/s12879-019-4588-9.","journal-title":"BMC Infect Dis"},{"key":"4883_CR33","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1590\/0037-8682-0136-2018","volume":"51","author":"G Sahal","year":"2018","unstructured":"Sahal G, Bilkay IS. Distribution of clinical isolates of Candida spp. and antifungal susceptibility of high biofilm-forming Candida isolates. Rev Soc Bras Med Trop. 2018;51:644\u201350.","journal-title":"Rev Soc Bras Med Trop"},{"key":"4883_CR34","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.mycmed.2019.07.006","volume":"29","author":"S Ghazi","year":"2019","unstructured":"Ghazi S, Rafei R, Osman M, Safadi EI, Mallat H, Papon N, et al. The epidemiology of Candida species in the Middle East and North Africa. J Mycol Med. 2019;29:245\u201352.","journal-title":"J Mycol Med"},{"key":"4883_CR35","unstructured":"Guidelines for management of opportunistic infections and antiretroviral treatment in adolescents and adults in Ethiopia. Addis Ababa Ethiopia: Federal HIV\/AIDS Prevention and Control Office Federal Ministry of Health; 2007."},{"key":"4883_CR36","doi-asserted-by":"publisher","first-page":"657","DOI":"10.2165\/00003495-199754050-00002","volume":"54","author":"BD Alexander","year":"1997","unstructured":"Alexander BD, Perfect JR. Antifungal resistance trends towards the year 2000: implications for therapy and new approaches. Drugs. 1997;54:657\u201378.","journal-title":"Drugs"},{"key":"4883_CR37","doi-asserted-by":"publisher","first-page":"e954","DOI":"10.1016\/j.ijid.2010.04.006","volume":"14","author":"ME Falagas","year":"2010","unstructured":"Falagas ME, Roussos N, Vardakas KZ. Relative frequency of albicans and the various non-albicans Candida spp. among candidemia isolates from inpatients in various parts of the world: a systematic review. Int J Infect Dis. 2010;14:e954\u201366.","journal-title":"Int J Infect Dis"},{"key":"4883_CR38","doi-asserted-by":"publisher","first-page":"3237","DOI":"10.1128\/JCM.01451-08","volume":"46","author":"M Desnos-Ollivier","year":"2008","unstructured":"Desnos-Ollivier M, Ragon M, Robert V, Raoux D, Gantier JC, Dromer F. Debaryomyces hansenii (Candida famata), a rare human fungal pathogen often misidentified as Pichia guilliermondii (Candida guilliermondii). J Clin Microbiol. 2008;46:3237\u201342.","journal-title":"J Clin Microbiol"},{"key":"4883_CR39","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1128\/JCM.02071-10","volume":"49","author":"RH Jensen","year":"2011","unstructured":"Jensen RH, Arendrup MC. Candida palmioleophila: characterization of a previously overlooked pathogen and its unique susceptibility profile in comparison with five related species. J Clin Microbiol. 2011;49:549\u201356.","journal-title":"J Clin Microbiol"},{"key":"4883_CR40","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1128\/JCM.01686-12","volume":"51","author":"A Mariana Castanheira","year":"2013","unstructured":"Mariana Castanheira A, Leah N, Woosley A, Daniel J, Diekema B, Ronald N, et al. Candida guilliermondii and Other Species of Candida Misidentified as Candida famata: Assessment by Vitek 2, DNA Sequencing Analysis, and Matrix-Assisted Laser Desorption Ionization\u2013Time of Flight Mass Spectrometry in Two Global Antifungal Surveillance Programs. J Clin Microbiol. 2013;51:117\u201324.","journal-title":"J Clin Microbiol"},{"issue":"4","key":"4883_CR41","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1128\/JCM.02363-09","volume":"48","author":"G. M. Lyon","year":"2010","unstructured":"Lyon GM, Karatela S, Sunay S, Adiri Y. Antifungal susceptibility testing of Candida isolates from the Candida surveillance study. J Clin Microbiol. 2010;48:1270\u20135.","journal-title":"Journal of Clinical Microbiology"},{"key":"4883_CR42","first-page":"501","volume-title":"Principles and practice of infectious diseases, vol. 1","author":"J Rex","year":"2005","unstructured":"Rex J, Stevens D. Systemic antifungal agents. In: Mandell G, Bennett J, Dolin R, editors. Principles and practice of infectious diseases, vol. 1. 6th ed. Philadelphia: Elsevier; 2005. p. 501\u201311.","edition":"6"},{"key":"4883_CR43","doi-asserted-by":"publisher","first-page":"12804","DOI":"10.5812\/jjm.12804","volume":"10","author":"S Hasanvand","year":"2017","unstructured":"Hasanvand S, Qomi HA, Kord M, Didehdar M. Molecular epidemiology and in vitro antifungal susceptibility of Candida isolates from women with vulvovaginal candidiasis in northern cities of Khuzestan Province. Iran Jundishapur J Microbiol. 2017;10:12804. https:\/\/doi.org\/10.5812\/jjm.12804.","journal-title":"Iran Jundishapur J Microbiol"},{"key":"4883_CR44","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s10096-003-1014-3","volume":"22","author":"LA Ostrosky-Zeichne","year":"2003","unstructured":"Ostrosky-Zeichne LA, Lashof MO, Kullberg BJ, Rex JH. Voriconazole salvage treatment of invasive candidiasis. Eur J Clin Microbiol Infect Dis. 2003;22:651\u20135.","journal-title":"Eur J Clin Microbiol Infect Dis"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-4883-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-020-4883-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-4883-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T00:19:21Z","timestamp":1616113161000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-020-4883-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,19]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["4883"],"URL":"https:\/\/doi.org\/10.1186\/s12879-020-4883-5","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,19]]},"assertion":[{"value":"14 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted after it was ethically reviewed and approved by the Ethical Review board of The Department of Medical Laboratory Sciences (DRERC) and Internal Review Board (IRB) of Arsho Advanced Medical Laboratory private limited company. Written consents were also obtained from participants. Assent form was completed and signed by a family member and\/or adult guardian for participants under the age of 16\u2009years.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable as details, images and\/or videos related to study subjects were not recorded for this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"231"}}